𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome

✍ Scribed by Drummond, M W; Lush, C J; Vickers, M A; Reid, F M; Kaeda, J; Holyoake, T L

Book ID
110055369
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
145 KB
Volume
17
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Imatinib mesylate in Philadelphia chromo
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood
✍ E. Anders Kolb; Qiulu Pan; Marc Ladanyi; Peter G. Steinherz πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 177 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Initial treatment for adult patients with Philadelphia chromosome‐positive (Ph[+]) chronic myelogenous leukemia (CML) now includes imatinib mesylate. However, to our knowledge, there are few data regarding imatinib safety, efficacy, and response monitoring in patients age

Outcome of patients with Philadelphia ch
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
✍ Hagop Kantarjian; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 150 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. ## METHODS. The outcome of 420 patients with CML post‐imatinib failure (resistance‐recurrence in 374; toxicities in 46) were reviewed in

Secondary myelodysplastic syndrome in a
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
✍ Arturo Vega-Ruiz; Susan O’Brien; Jorge Cortes; Partow Kebriaei; Deborah Thomas; πŸ“‚ Article πŸ“… 2008 πŸ› Elsevier Science 🌐 English βš– 90 KB

The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in c